SOURCE: Rheologics Technologies, Inc.

January 24, 2007 19:50 ET

Rheologics Announces Changes to Board of Directors

EXTON, PA -- (MARKET WIRE) -- January 24, 2007 -- Rheologics Technologies, Inc. (PINKSHEETS: RTGI), the leader in the study of blood viscosity and its relationship to cardiovascular disease, is pleased to announce the appointment of Kenneth R. Kensey, MD, and Daniel J. Cho to its board of directors. Additionally, the Company announced that Alfonso Knoll and Beau Kelley have resigned as members of the board of directors.

Both Kensey and Cho have held management positions at Rheologics, Inc., a subsidiary of Rheologics Technologies, Inc. They will continue to serve in their respective capacities at the operating company level. Their appointment to the board of directors of the parent Rheologics Technologies, Inc. underscores the Company's focus on the commercialization of innovative diagnostics and therapeutics for cardiovascular disease.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.

Contact Information